The best of both worlds
Medicilon/MPI Preclinical Research-Shanghai,
a joint venture between US-based MPI Research
and Chinese company Shanghai Medicilon, is committed
to providing Sponsors quality research in an Asian
facility that meets worldwide regulatory standards.
 In
December 2007 two businesses came together for
one mission – to meet the growing needs of
the multinational pharmaceutical and biotech industries.
MPI Research from the US and China’s Shanghai
Medicilon joined forces to create Medicilon/MPI
Preclinical Research-Shanghai, a company that
provides global pharmaceutical and biotechnology
companies with high-quality preclinical drug discovery
and development studies in an Asian facility that
meets worldwide regulatory standards.
Medicilon/MPI Preclinical Research-Shanghai is
meeting the
needs of Sponsors around the globe while conducting
studies
that comply with US FDA Good Laboratory Practices
(GLP)
regulations. In addition to conducting GLP studies,
the company
has been recognised as an accredited International
Association
for Assessment and Accreditation of Laboratory
Animal Care
(AAALAC) facility.
These recent advancements further underscore the
company’s
commitment to providing Sponsors with quality
research. A full
AAALAC accreditation is a reflection of high standards,
accountability and a commitment to animal welfare.
This
achievement is recognised as a milestone and benchmark
for
responsible and ethical laboratory animal care,
and also sets
standards for veterinary medical care, occupational
health and
safety, and physical plant or HVAC standards that
rival or
exceed those of many non-accredited Western institutions.
Medicilon/MPI Preclinical Research-Shanghai recognises
that
the implementation of these standards did not
come without
challenges. It was a top priority to find quality
suppliers of
animals and animal feed, and the company decided
to adjust its
launch date for GLP offerings in order to guarantee
its Sponsors
the topmost quality. The process of finding the
right team to
bring the company to the highest standards required
nearly two
years of close collaboration between parent companies
Shanghai
Medicilon and MPI Research.
High-class personnel
A team of five people from the corporate headquarters
of MPI Research in Mattawan, Michigan accepted
long-term assignments in China and trained local
employees on GLP and AAALAC standards for animal
care and use. At times, this team was supplemented
with more than a dozen people based on scientific
focus areas, and also had help from three key
players: Dr. Jintao Zhang, CEO, Dr. Mingli Chen,
VP of Toxicology, and Dr. Lijie Fu, executive
VP of Operations. Dr. Zhang is founder of Shanghai
Medicilon Inc. and has extensive experience of
both US- and China-based CROs. Originally from
China, Dr. Chen, MD, MS, DABT, a board-certified
toxicologist with significant pharma and CRO experience
in the US, returned to the country to apply her
expertise. Dr. Fu, PhD, another national returnee,
brings substantial scientific experience, along
with experience from other China-based CROs.
With more than 62,000ft² of preclinical research
capacity, and
a staff of more than 120 dedicated employees,
the company
takes pride in its state-of-the-art facility that
is optimally
designed for GLP toxicology, safety and efficacy
studies. In
addition to these capabilities, the company also
offers Sponsors
ADME, PK/TK, analytical and bioanalytical services.
Medicilon/MPI Preclinical Research-Shanghai is
continually
looking for ways to meet the needs of the industry.
The company
has a dedicated team that provides high quality,
timely service
to its Sponsors. This team ensures top quality
research by
modelling their parent companies’ use of
superior systems,
proper standard operating procedures (SOPs) and
extensive
training programmes, and by employing an active
QA staff and
recruiting the best talent in the industry.
|
 |
Company profile
Medicilon/MPI Preclinical Research-Shanghai
For further information, visit: www.medicilon-mpi.com
Email: info@medicilon-mpi.com
|
